The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-B79 phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients.
 
Richard D. Kim
Consulting or Advisory Role - Bayer; Exelixis; Lilly; QED Therapeutics; SERVIER; Taiho Oncology
Speakers' Bureau - Incyte; Lilly
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
 
Hans Prenen
Honoraria - Amgen; Bayer; Roche; Sanofi
 
Sylvie Rottey
No Relationships to Disclose
 
Dae Won Kim
Research Funding - Bold Therapeutics
 
Anne Flament
Employment - Celyad Oncology
 
Frederic Lehmann
Employment - Celyad Oncology
Leadership - Celyad Oncology
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)